In the study presented here, VSV treatment of CCA in rats led to therapeutic modulation of fibrosis and downregulation of TGF-β and the HSC activation marker, α-SMA, concomitantly with a decrease in collagen levels. The gene discussed is TGFB1; the disease is cholangiocarcinoma.